Advertisement

Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization

      Abstract

      The association between peripheral vascular disease and outcomes after percutaneous coronary intervention was examined in the Do Tirofiban and Reopro Give Similar Efficacy Outcome Trial (TARGET). After adjustments in a multivariate model, a history of peripheral vascular disease was found to be associated with a two- to threefold increase in mortality at 1 year after coronary stent placement.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Criqui M.H.
        • Fronek A.
        • Barrett-Connor E.
        • Klauber M.R.
        • Gabriel S.
        • Goodman D.
        The prevalence of peripheral arterial disease in a defined population.
        Circulation. 1985; 71: 510-515
        • Moliterno D.J.
        • Topol E.J.
        • TARGET International Steering Committee
        A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement.
        Am Heart J. 2000; 140: 722-726
        • Topol E.J.
        • Moliterno D.J.
        • Herrmann H.C.
        • Powers E.R.
        • Grines C.L.
        • Cohen D.J.
        • Cohen E.A.
        • Bertrand M.
        • Neumann F.
        • Stone G.W.
        • DiBattiste P.M.
        • Demopoulos L.
        • TARGET Investigators
        Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
        N Engl J Med. 2001; 344: 1888-1894
        • Moliterno D.J.
        • Yakubov S.J.
        • DiBattiste P.M.
        • Herrmann H.C.
        • Stone G.W.
        • Macaya C.
        • Neumann F.
        • Ardissino D.
        • Bassand J.
        • Borzi L.
        • et al.
        • TARGET Investigators
        Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement.
        Lancet. 2002; 36: 355-360
        • Criqui M.H.
        • Langer R.D.
        • Fronek A.
        • Feigelson H.S.
        • Klauber M.R.
        • McCann T.J.
        • Browner D.
        Mortality over a period of 10 years in patients with peripheral arterial disease.
        N Engl J Med. 1992; 326: 381-386
        • Papamichael C.M.
        • Lekakis J.P.
        • Stamatelopoulos K.S.
        • Papaioannou T.G.
        • Alevizaki M.K.
        • Cimponeriu A.T.
        • Kanakakis J.E.
        • Papapanagiotou A.
        • Kalofoutis A.T.
        • Stamatelopoulos S.F.
        Ankle-brachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease.
        Am J Cardiol. 2000; 86: 615-618
        • Vogt M.T.
        • McKenna M.
        • Wolfson S.K.
        • Kuller L.H.
        The relationship between ankle brachial index, other atherosclerotic disease, diabetes, smoking and mortality in older men and women.
        Atherosclerosis. 1993; 101: 191-202
        • Vogt M.T.
        • Cauley J.A.
        • Newman A.B.
        • Kuller L.H.
        • Hulley S.B.
        Decreased ankle/arm blood pressure index and mortality in elderly women.
        JAMA. 1993; 270: 465-469
        • CAPRIE Steering Committee
        A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE).
        Lancet. 1996; 348: 1329-1339